Please use this identifier to cite or link to this item:
|Statistics||SHARE CORE MendeleyBASE||
|Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL|
Granulocyte–monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis
|Authors:||Rodríguez-Lago, Iago; Sempere, Laura; Gutiérrez, Ana; Núñez Ortiz, Andrea; Leo Carnerero, Eduardo; Hinojosa, Esther; Mora, María; Cañete, Fiorella; Mañosa, Miriam; Herrera, Claudia; Beltrán, Belén; Forés, Ana; Arjona, Dolores; Barreiro-de Acosta, M.; Khorrami, Sam; Aguirre, Urko; Ginard, Daniel; Cabriada, José Luis|
Loss of response
|Publisher:||Taylor & Francis|
|Citation:||Scandinavian Journal of Gastroenterology 54(4): 459-464 (2019)|
|Abstract:||[Objective] To evaluate the effectiveness and safety of the combination of granulocyte–monocyte apheresis (GMA) after loss of response (LOR) to anti-tumor necrosis factor (TNF) agents in ulcerative colitis (UC).|
[Materials and methods] A retrospective, multicenter study was performed in 11 inflammatory bowel disease (IBD) Units. Clinical remission was defined as a partial Mayo score ≤2. The effectiveness of the treatment was evaluated by the partial Mayo score and the rate of anti-TNF intensification, switch, swap or colectomy.
[Results] Forty-seven patients with ulcerative colitis were included (mean age 35 years, mean disease duration 52 months, 66% male and 59% extensive colitis). Twenty-three subjects were receiving infliximab, eighteen adalimumab and six golimumab. GMA was combined after a primary non-response (49%) or secondary loss of response (51%) to anti-TNF therapy. We observed a significant decrease in partial Mayo score and fecal calprotectin after GMA. Fifteen patients (32%) responded to the combination therapy without anti-TNF intensification, switch, swap or colectomy. Eight patients (17%) underwent colectomy. Two patients (4%) presented adverse events related to the technique.
[Conclusions] Combination of GMA and anti-tumor necrosis factor is a safe and effective treatment after the loss of response to these biologic agents, with a significant decrease of the clinical disease activity and biomarkers, in a population with limited therapeutic alternatives.
|Publisher version (URL):||http://dx.doi.org/10.1080/00365521.2019.1600715|
|Appears in Collections:||(IBIS) Artículos|